SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001193125-19-125776
Filing Date
2019-04-29
Accepted
2019-04-29 17:29:04
Documents
16
Period of Report
2019-06-25
Effectiveness Date
2019-04-29

Document Format Files

Seq Description Document Type Size
1 DEF 14A d734420ddef14a.htm DEF 14A 699587
2 GRAPHIC g7344201.jpg GRAPHIC 47006
3 GRAPHIC g73442010.jpg GRAPHIC 2430
4 GRAPHIC g73442011.jpg GRAPHIC 2465
5 GRAPHIC g7344202.jpg GRAPHIC 43955
6 GRAPHIC g7344203.jpg GRAPHIC 1609
7 GRAPHIC g7344204.jpg GRAPHIC 5462
8 GRAPHIC g7344205.jpg GRAPHIC 1378
9 GRAPHIC g7344206.jpg GRAPHIC 2345
10 GRAPHIC g7344207.jpg GRAPHIC 1574
11 GRAPHIC g7344208.jpg GRAPHIC 8824
12 GRAPHIC g7344209.jpg GRAPHIC 42369
13 GRAPHIC g734420g08i61.jpg GRAPHIC 28371
14 GRAPHIC g734420g33q91.jpg GRAPHIC 41162
15 GRAPHIC g734420g85m10.jpg GRAPHIC 28889
16 GRAPHIC g734420x_1.jpg GRAPHIC 860
  Complete submission text file 0001193125-19-125776.txt   1058911
Mailing Address 480 PLEASANT STREET SUITE B300 WATERTOWN MA 02472
Business Address 480 PLEASANT STREET SUITE B300 WATERTOWN MA 02472 617-926-5000
EyePoint Pharmaceuticals, Inc. (Filer) CIK: 0001314102 (see all company filings)

IRS No.: 262774444 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 000-51122 | Film No.: 19777290
SIC: 3826 Laboratory Analytical Instruments